All articles tagged with #vera therapeutics
The FDA approved Vera Therapeutics' drug Trutakna to treat IgA nephropathy, a chronic autoimmune kidney disease that can progress to kidney failure, marking a milestone for Vera and advancing biotech options for patients.
Otsuka's experimental drug sibeprenlimab showed promising results in reducing toxic protein levels in patients with IgA nephropathy, outperforming Vera Therapeutics in a Phase 3 study, with fewer serious side effects.
Vera Therapeutics announced positive Phase 3 trial results for its kidney disease drug atacicept, which significantly reduced proteinuria in patients with IgA nephropathy, supporting a potential FDA submission later this year.